Literature DB >> 8777086

The clinical impact of vertebral fractures: quality of life in women with osteoporosis.

D T Gold1.   

Abstract

Osteoporosis has obvious physical and functional consequences such as kyphosis, restricted range of motion, and pain. What are not so obvious are the psychosocial sequelae that result from this metabolic bone disease. Many patients in the initial phases of the disease express substantial anxiety, especially about the possibility of future fractures and physical deformity. As the disease progresses, depression can become profound for those who experience hip or multiple vertebral fractures. The effects of the chronicity of osteoporosis, its disabling and disfiguring aspects, and the chronic postural pain that develops as time passes challenge even the most stable individuals. In addition, osteoporosis has substantial impact on interpersonal relationships and social roles. The dependency created by this disease affects close relationships, because the patient with osteoporosis cannot reciprocate in social support. Today's older women find the restrictions of the disease socially devastating. These women, unlikely to work in the labor force, took pride in their roles of housekeeper and cook. Unfortunately, severe osteoporosis can force women to relinquish even these social roles, leaving them with no source of self-esteem or accomplishment. In all, osteoporosis is devastating both psychologically and socially.

Entities:  

Mesh:

Year:  1996        PMID: 8777086     DOI: 10.1016/8756-3282(95)00500-5

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  94 in total

1.  [Filler materials for augmentation of osteoporotic vertebral fractures].

Authors:  M Arabmotlagh; M Rauschmann
Journal:  Orthopade       Date:  2010-07       Impact factor: 1.087

Review 2.  Osteoporosis and depression: a historical perspective.

Authors:  Deborah T Gold; Samantha Solimeo
Journal:  Curr Osteoporos Rep       Date:  2006-12       Impact factor: 5.096

3.  Comparison of the analgesic efficacy of pamidronate and synthetic human calcitonin in osteoporotic vertebral fractures: a double-blind controlled study.

Authors:  M Laroche; S Cantogrel; B Jamard; A Constantin; L Zabraniecki; A Cantagrel; B Mazières
Journal:  Clin Rheumatol       Date:  2006-01-04       Impact factor: 2.980

4.  Canadian Consensus Conference on osteoporosis, 2006 update.

Authors:  Jacques P Brown; Michel Fortier; Heather Frame; André Lalonde; Alexandra Papaioannou; Vyta Senikas; Chui Kin Yuen
Journal:  J Obstet Gynaecol Can       Date:  2006-02

5.  Lordoplasty: report on early results with a new technique for the treatment of vertebral compression fractures to restore the lordosis.

Authors:  Rene Orler; Lars H Frauchiger; Uta Lange; Paul F Heini
Journal:  Eur Spine J       Date:  2006-05-25       Impact factor: 3.134

6.  Health state utility values and patient-reported outcomes before and after vertebral and non-vertebral fractures in an osteoporosis clinical trial.

Authors:  T Imai; S Tanaka; K Kawakami; T Miyazaki; H Hagino; M Shiraki
Journal:  Osteoporos Int       Date:  2017-03-06       Impact factor: 4.507

7.  The hospital cost of vertebral fractures in the EU: estimates using national datasets.

Authors:  Henrik W Finnern; David P Sykes
Journal:  Osteoporos Int       Date:  2003-04-30       Impact factor: 4.507

Review 8.  The impact of fragility fracture on health-related quality of life : the importance of antifracture therapy.

Authors:  Ted Xenodemetropoulos; Shawn Davison; George Ioannidis; Jonathan D Adachi
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

Review 9.  A risk-benefit assessment of alendronate in the treatment of involutional osteoporosis.

Authors:  J P Devogelaer
Journal:  Drug Saf       Date:  1998-08       Impact factor: 5.606

10.  Psychological state, quality of life, and body composition in postmenopausal women with osteoporosis in Lithuania.

Authors:  Lina Lasaite; Aurelija Krasauskiene
Journal:  Arch Osteoporos       Date:  2009-12-01       Impact factor: 2.617

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.